Intrexon Corporation Secures $25 Million Series C-2 Investment
Blacksburg, VA: Intrexon Corporation, a privately held life sciences company focused on biotherapeutic control systems, announced today it has closed a $25 million Series C-2 financing by New River Management V, LP, a private investment fund managed by Third Security, LLC. Previous rounds of investment have been provided by New River Management IV,LP, New River Management V and NewVa Capital Partners, LP, a regional investment partnership. Funds and other entities managed by Third Security have invested a total of $56.5 million in Intrexon to date.
According to Intrexon CEO Robert Beech, “The encouraging results from our ongoing clinical and pre-clinical studies have established the basis for expanding our R&D activities toward other disease areas and industry relationships. We greatly appreciate this level of support and commitment from our investors.”
“We are pleased to make this additional investment in Intrexon,” said R.J. Kirk, Chairman and CEO of Third Security, “The company has developed a number of elegant approaches to solve problems that have limited the impact of many biotherapeutics. We believe that Intrexon’s technology should enhance the safety and efficacy of existing and novel biotherapies.”